Lithium naphthalenide induced reductive alkylation of α-cyano ketones. A general method for regiocontrol of α, α-dialkylation of ketones
作者:Hsing-Jang Liu、Jia-Liang Zhu、Kak-Shan Shia
DOI:10.1016/s0040-4039(98)00780-1
日期:1998.6
An efficient generalmethod for the consecutive introduction of two alkyl groups to the α carbon of a ketone carbonyl has been developed, making use of the lithium naphthalenide induced reductive alkylation of an α-cyano ketone system as a key operation.
Asymmetric Synthetic Access to the Hetisine Alkaloids: Total Synthesis of (+)-Nominine
作者:Kevin M. Peese、David Y. Gin
DOI:10.1002/chem.200701290
日期:2008.2.8
A dual cycloaddition strategy for the synthesis of the hetisinealkaloids has been developed, illustrated by a concise asymmetric total synthesis of (+)-nominine (7). The approach relies on an early-stage intramolecular 1,3-dipolar cycloaddition of a 4-oxido-isoquinolinium betaine dipole with an ene-nitrile dipolarophile. Subsequent late-stage pyrrolidine-induced dienamine isomerization/Diels-Alder
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
申请人:Sepracor Inc.
公开号:EP2617704A1
公开(公告)日:2013-07-24
Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g. from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
申请人:Sunovion Pharmaceuticals Inc.
公开号:EP3296289A2
公开(公告)日:2018-03-21
Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g. from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.